Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644 1671
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18271206 | MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS | Non-Final OA | The Regents of the University of California |
| 18255094 | COMBINATIONS OF SMALL MOLECULE DRUG CONJUGATE AND CAR-EXPRESSING CYTOTOXIC LYMPHOCYTES AND METHODS OF TREATING CANCER USING THE SAME | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18567197 | MATERIALS AND METHODS FOR DIFFERENTIATING CREB REGULATEDTRANSCRIPTION COACTIVATOR 3 | Non-Final OA | The General Hospital Corporation |
| 18273395 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES | Non-Final OA | The General Hospital Corporation |
| 17627975 | SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER | Final Rejection | The General Hospital Corporation |
| 18548481 | TARGETING T REGULATORY CELLS TO ISLET CELLS TO STALL OR REVERSE TYPE 1 DIABETES | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy